Tags : Molecular Templates

Biotech

Vertex Collaborates with Molecular Templates to Discover and Develop Conditioning

Shots: Molecular Templates (MTEM) to receive $38M up front including an equity investment, up to $522M as development, regulatory, commercial milestones, option payment for two targets and royalties on sales of products MTEM will conduct research activities to discover a new conditioning regimen utilizing its engineered toxin body (ETB) platform for up to two targets […]Read More

M&A

Takeda signs a Co-Development Agreement with Molecular Templates for CD38-Targeted

Shots: Takeda will provide upfront of $30M and to pay royalties on commercialization. CD38-Targeted ETBs’ development cost will be shared equally between both the parties Molecular Templates will receive development, regulatory and commercial milestone payments of up to $632.5M if company exercise its co-development option, or $337.5M if it does not exercise or opts out […]Read More